Verastem reports KRAS pancreatic cancer data, $250M raise, CEO exit

· Health · United States

Verastem Oncology announced new data for its KRAS-targeted cancer drug in a small study, alongside a $250 million raise and the departure of its chief executive, all on the same morning. Analysts described the results as making the Massachusetts company's drug "competitive" in what has become one of the most crowded areas of oncology research, where it would take on rivals including Revolution Medicines. KRAS was long considered undruggable, and the recent wave of agents targeting it has drawn heavy investment across large and small drugmakers. The combination of fresh clinical data, a capital raise to fund further development and a leadership change signals that Verastem intends to press its claim in pancreatic cancer, a disease with few effective options, while repositioning its executive team for the next phase.

Why it matters：KRAS is now one of oncology's most competitive races, and Verastem's data, funding and leadership change show how smaller biotechs must raise capital and shuffle management to stay in it.

Key points

  • The data come from a small study in pancreatic cancer.
  • Analysts called the drug competitive in the crowded KRAS field.
  • The company also announced a $250 million raise and its CEO's departure.

Sources (original reporting)

More stories from this day